Diabetes technology has been one of the most resilient markets during the pandemic, with companies like Dexcom, Tandem Diabetes Care and Insulet growing revenues and users as the adoption of wearable devices and digital health technologies have taken off.
Along with the recent pandemic pressure, and some seasonal slowdown from the company’s strategy shift to distributing CGMs through pharmacies rather than the durable medical equipment channel, Dexcom has been forced to push back the launch of its upcoming G7 CGM system.
